Ever Supreme's Allogeneic CAR-T CAR001 Clears Phase I Safety Review, Advances to Phase IIa in Solid Tumors
Key Insights
Ever Supreme's allogeneic "off-the-shelf" CAR-T therapy CAR001 has received Safety Monitoring Committee clearance to advance into Phase IIa clinical trials following a successful Phase I dose-escalation study.
Phase I data demonstrated an excellent safety profile and preliminary efficacy signals in solid tumors, including a Complete Response in a glioblastoma (search) patient and tumor reduction in colorectal cancer.
CAR001 eliminates the need for lymphodepletion chemotherapy, preserving the patient's immune environment and enabling a synergistic anti-tumor effect via its BiTE mechanism.
TAICHUNG, June 29, 2026 — Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed allogeneic "off-the-shelf" CAR-T cell therapy, has successfully cleared review by the Safety Monitoring Committee (SMC). Following a thorough evaluation of the Phase I safety profile and preliminary efficacy data, the committee has greenlit advancement to the Phase IIa clinical trial, marking the successful completion of the critical safety assessment during Phase I dose-escalation and establishing a foundation for global licensing partnerships and multi-country, multi-center clinical trials.
Phase I Safety and Efficacy: Signals in Treatment-Resistant Solid Tumors
Traditional CAR-T therapies have faced significant obstacles in solid tumors, including an inhibitory tumor microenvironment, poor CAR-T infiltration, and persistent safety concerns. CAR001 demonstrated an excellent safety profile in its Phase I trial while producing clinically meaningful preliminary efficacy signals in highly treatment-resistant solid tumors, including glioblastoma (search) (GBM) and microsatellite stable colorectal cancer (search) (MSS CRC).
Notably, a case of malignant brain cancer treated with CAR001 achieved a Complete Response (CR), with all detectable signs of the tumor disappearing. Additionally, a colorectal cancer patient showed a noticeable reduction in tumor size. These outcomes, according to the company, highlight the powerful development potential of CAR001 in tackling solid tumors.
A Differentiated Approach: Eliminating Lymphodepletion Chemotherapy
A key competitive advantage of CAR001 is that patients do not need to undergo lymphodepletion — a form of preparatory chemotherapy — before receiving the cell infusion. Historically, such chemotherapy was required to clear immune-suppressing cells and prevent the patient's body from destroying the introduced CAR-T cells. However, this comes at a heavy cost, significantly increasing the risk of infection and causing side effects such as anemia, cytokine release syndrome (CRS), neurotoxicity, and general chemotherapy toxicity.
By eliminating the need for lymphodepletion, CAR001 improves clinical convenience and spares patients from the toxic risks of traditional chemo pre-treatment. Crucially, this approach preserves the patient's existing immune environment, allowing the bispecific T-cell engager (BiTE) mechanism secreted by CAR001 to actively recruit and bond with the patient's own T cells, creating a synergistic anti-tumor attack that significantly enhances the overall therapeutic effect.
Allogeneic Gamma-Delta T Cell Platform: Built for Mass Production
CAR001 utilizes healthy donor-derived, allogeneic gamma-delta (γδ) T cells as its core cell source. Compared to the alpha-beta (αβ) T cells used in traditional therapies, γδ T cells carry a much lower risk of triggering Graft-versus-Host Disease (GvHD), making them exceptionally well-suited for development into "off-the-shelf" cell therapy products.
This allogeneic platform bypasses the steep limitations of traditional autologous CAR-T therapies — including inconsistent cell quality among severely ill patients, lengthy manufacturing wait times, and capped production capacity. Instead, CAR001 delivers immediate "off-the-shelf" availability, commercial mass production, and vastly expanded clinical accessibility, fundamentally shifting the landscape for solid tumor patients who currently lack effective cell therapy options.
Phase IIa Design and Strategic Commercial Objectives
The upcoming Phase IIa clinical trial will focus on accumulating vital data across key clinical benchmarks, including Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DoR), and Overall Survival (OS). According to Ever Supreme, when global pharmaceutical giants evaluate early-stage innovative therapies for licensing or co-development, they place immense weight on safety records, preliminary efficacy signals, commercial scalability, clinical convenience, and a clear regulatory pathway. The continued accumulation of Phase IIa data is expected to significantly elevate the company's commercial leverage and valuation in licensing negotiations.
Regulatory Pathway Under Taiwan's Regenerative Medicine Acts
With the official implementation of Taiwan's twin Regenerative Medicine Acts, a strategic pathway has opened for life-threatening or severely disabling diseases. If a regenerative medicine product demonstrates exceptional safety and efficacy during clinical trials, developers can apply for a conditional, five-year drug approval. Ever Supreme stated that following the official launch of the CAR001 Phase IIa trial, the company will aggressively push forward with clinical data collection and, if results continue to support safety and therapeutic potential, will actively evaluate the feasibility of applying for conditional approval under Taiwan's Regenerative Medicine Products Act.
Building Toward Global Multi-Center Phase IIb Trials
Ever Supreme emphasized that the first-stage clinical results of CAR001 not only validate its safety and scientific innovation but also provide a cornerstone for future clinical enrollment expansion, international licensing, and global development strategies. Based on the unfolding Phase IIa data, the company plans to map out and launch global, multi-country, multi-center clinical trials. By actively pursuing licensing deals or co-development partnerships with international pharmaceutical companies, Ever Supreme aims to accelerate CAR001's clinical development across the global solid tumor market, ultimately delivering a new therapeutic option to cancer patients worldwide.